Simultaneous use of biologic agents in combination or with Xeljanz may be a viable treatment option for highly selected, refractory patients with inflammatory bowel disease, according to study results.

Robert Battat, MD, from the Jill Roberts Center for IBD at Weill Cornell Medicine, and colleagues wrote that many patients with IBD experience loss of response or are primary non-responders despite advances in therapies and drug optimization.

“Approximately only 40% of patients with response to biologic therapies maintain clinical remission at 1 year,” they wrote. “Drug-related

Full Article: